Finance entity
All 2 tracked stories fall under one category: markets. Of the tracked stories, 2 of 2 also mention Dow Jones Industrial Average, the most common co-covered peer. Source depth averages 7 original sources per story, versus 3.8 across the same-window beat baseline.
Last mentioned: Aug 27, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: markets. Of the tracked stories, 2 of 2 also mention Dow Jones Industrial Average, the most common co-covered peer. Source depth averages 7 original sources per story, versus 3.8 across the same-window beat baseline. At 6, the average consequence score sits below the same-window beat average of 6.4. This profile follows 2 Finance stories mentioning Abbott Laboratories across the period from July 16, 2026 to July 20, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 79 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Abbott Laboratories. Shared-story counts are live from our verified record — not editorial picks.
While the S&P 500 slipped 0.5% on July 16, the decline was entirely attributable to a handful of overvalued AI chip stocks. Nearly three-quarters of index members rose, with healthcare and freight sectors rallying. The sell-off reveals a powerful rotation under the surface that could reshape portfolio allocations.
A concentrated sell-off in AI-driven chipmakers slammed the Nasdaq on July 16, even as strong earnings from healthcare and freight companies boosted over 75% of S&P 500 stocks. The divergence underscores a market rotation that threatens index-level returns while creating pockets of opportunity in undervalued sectors. Rising oil prices add a macro risk that could further pressure tech valuations.
Source: thetimes-tribune.com · advocate-news.com
Abbott Laboratories is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
